Pancreatic endocrine tumors - Management guidelines (recommended by the Polish Network of Neuroendocrine Tumors);Guzy endokrynne trzustki (zasady postȩpowania rekomendowane przez Polska̧ Sieć Guzów Neuroendokrynnych)

Endokrynologia Polska

Volumn 59, Issue 1, 2008, Pages 68-86

  Kos Kudła, Beata ^a   Bolanowski, Marek ^b   Hubalewska Dydejczyk, Alicja ^c   Krzakowski, Maciej ^d   Marek, Bogdan ^a   Nasierowska Guttmejer, Anna ^d   Lampe, Paweł ^a   Sworczak, Krzysztof ^e   Bar Andziak, Ewa ^f   Ćwikła, Jarosław ^g   Dzielicki, Józef ^h   Falconi, Massimo ⁱ   Foltyn, Wanda ^j   Gaciong, Zbigniew ^k   Handkiewicz Junak, Daria ^l   De Herder, Wouter ^m   Jarza̧b, Barbara ^l   Jeziorski, Arkadiusz ⁿ   Kowalska, Aldona ^o   Kryszałowicz, Bozena ^p   Królicki, Leszek ^q   Krzyzanowska Świniarska, Barbara ^r   Kunikowska, Jolanta ^q   Kvols, Larry ^s   O'Toole, Dermot ^t   Matyja, Violetta ^j   Mełeń Mucha, Gabriela ^u   Milewicz, Andrzej ^v   Nowak, Andrzej ^a   Nowakowska Duława, Ewa ^a   Omyła Staszewska, Joanna ^w   Paja̧k, Jacek ^a   Rudzki, Sławomir ^x   Sowiński, Jerzy ^y   Starzyńska, Teresa ^r   Strzelczyk, Janusz ^j   Syrenicz, Anhelli ^z   Szawłowski, Andrzej ^d   Tomaszewska, Romana ^c   Waśko Czopnik, Dorota ^b   Wroński, Marek ^aa   Zajȩcki, Wojciech ^a   Zemczak, Anna ^j   Zgliczyński, Wojciech ^ab   more..

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^h Katedra I Klinika Chirurgii Wad Rozwojowych Dzieci I Traumatologii lAM   (Poland)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j Klinika Endokrynologii   (Poland)

^k AM   (Poland)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ Klinika Chirurgii Onkologicznej   (Poland)

^o Dzia Endokrynologii CO   (Poland)

^p Leczenia Nieswoistych Chorob Zapalnych Jelit   (Poland)

^q Zak ad Medycyny Nuklearnej SP CSK   (Poland)

^r POMERANIAN MEDICAL UNIVERSITY   (Poland)

^s UNIVERSITY OF SOUTH FLORIDA   (United States)

^t ST JAMES S HOSPITAL   (Ireland)

^u MEDICAL UNIVERSITY OF LODZ   (Poland)

^v Klinika Endokrynologii   (Poland)

^w Klinika Onkologii   (Poland)

^x Medical University of Lublin I Katedra i Klinika Chirurgii Ogolnej i Transplantacyjnej   (Poland)

^y POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^z Nadci nienia Tetniczego i Chorób Przemiany Materii Pomorskiej AM w Szczecinie   (Poland)

^aa WIM   (Poland)

^ab MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

more..

Author keywords

Diagnosis; Pancreatic endocrine tumors; Therapy

Indexed keywords

DIAZOXIDE; DOXORUBICIN; FLUOROURACIL; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR; STREPTOZOCIN; DIAGNOSTIC AGENT; SOMATOSTATIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SURGERY; GASTRINOMA; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; INSULINOMA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRACTICE GUIDELINE; REVIEW; SOMATOSTATINOMA; ARTICLE; CANCER STAGING; CLINICAL COMPETENCE; ENDOSCOPIC ECHOGRAPHY; METHODOLOGY; PHYSICAL EXAMINATION; POLAND; RISK FACTOR;

CLINICAL COMPETENCE; ENDOSONOGRAPHY; HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHYSICAL EXAMINATION; POLAND; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 42249107500     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (195)

1. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer 2004; 11: 1-18.
2. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62: 51-58.
3. Eriksson B, Arnberg H, Lindgreen PG i wsp. Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990; 228: 103-113.
4. Modlin IM, Lye KD, Kidd M. A 5 decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
5. Marion-Aubidert AM, Barel C, Gouysse G i wsp. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocirne tumors. Gastroenterology 2003; 125: 1094-1104.
6. Couvelard A, O'Toole D, Turley H i wsp. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumors: negative correlation of microvascular density and VEGF expression with tumor progression. Br J Cancer 2005; 92: 94-101.
7. Pape UF, Bohmig M, Berndt U i wsp. Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann NY Acad Sci 2004; 1014: 222-233.
8. Corleto VD, Panzuto F, Falconi M i wsp. Digestive neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Ilalian Society of Gastroenterology (SIGE). Dig Liver Dis 2001; 33: 217-221.
9. Falconi M, Plockinger U, Kwekkeboom DJ i wsp. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211.
10. O'Toole D, Salazar R, Falconi M i wsp. Rare Functioning Pancreatic Endocrine Tumors. Neuroendocrinology 2006; 84: 189-195.
11. Danforth DN Jr, Gorden P, Brennan MF. Metastatic insulin secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 1984; 96: 1027-1037.
12. de Herder WW, Niederle B, Scoazec J-Y i wsp. Well-deifferentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-188.
13. Steinmüller T, Kianmanesh R, Falconi M i wsp. Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology 2008; 87: 47-62.
14. Norton JA. Gastrinoma: advances in localization and treatment. Surg Oncol Clin N Am 1998; 7: 845-861.
15. Jensen RT. Zollinger-Ellison syndrome. W: Doherty GM, Skogseid B (red.). Surgical endocrinology: clinical syndromes. Lippincott Williams & Wilkins, Philadelphia 2001; 291-344.
16. Jensen RT, Niederle B, Mitry E i wsp. Gastrinoma (duodenal and pancreatic) Neuroendocrinology 2006; 84: 173-182.
17. Weber HC, Venzon DJ, Lin JT i wsp. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
18. Pipeleers-Marichal M, Donow C, Heitz PU i wsp. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type 1. Wold J Surg 1993; 17: 481-488.
19. Yu F, Venzon DJ, Serrano J i wsp. Prospective study of the clinical course, prognostic factors and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630.
20. Jensen RT. Natural history of digestive endocrine tumors. W: Mignon M, Colombel JF (red.). Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. John Libbey Eurotext Publishing, Paris 1999; 192-219.
21. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773.
22. Corleto VD, Delle Fave G, Jensen RT. Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis 2002; 34: 668-680.
23. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med 1986; 315: 1-5.
24. Cadiot G, Vuagnat A, Doughan I i wsp. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 1999; 116: 286-293.
25. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 25: 374-380.
26. Mallinson CN, Bloom SR, Warin AP i wsp. A glucagonoma syndrome. Lancet 1974; 1-5.
27. Ganda OP, Weir GC, Soeldner JS i wsp. Somatostatinoma: a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 1977; 296: 963-967.
28. Soga J. Statistical evaluation of 2001 carcinoid cases with metastases, collected from, iterature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res 1998; 17: 3-12.
29. Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Res 1999; 18: 13-22.
30. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspective. Am J Med Sci 2001; 321: 306-320.
31. Broder LE, Carter SK. Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med 1973; 79: 101-107.
32. Klimstra DS PA, Öberg K, Komminoth P i wsp. Non-Functioning Tumors and Nicroaadenomas. IARC Press, Lyon 2004.
33. Delaunit T, Ducreux M, Boige V i wsp. The doxorubicin streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004; 40: 515-520.
34. La Rosa S, Sessa F, Capella C i wsp. Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 1996; 429: 323-333.
35. Broughan TA, Leslie JD, Soto JM i wsp. Pancreatic islet cell tumors. Surgery 1986; 99: 671-678.
36. Chu QD, Hill HC, Douglass HO i wsp. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855-862.
37. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32: 203-208.
38. Eriksson B, Skogseid B, Lundqvist G i wsp. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883-1890.
39. Konoshita K, Minari Y, Ohmori Y i wsp. Curative resection of a small cell carcinoma of the pancreas report of a case of long survival without chemotherapy. J Gastroenterol Hepatol 2004; 19: 1087-1091.
40. Morohoshi T, Held G, Klöppel G. Exocrine pancreatic tumors and their histological classification a study based on 167 autopsy and 97 surgical cases. Histopathology 1983; 7: 645-661.
41. O'Connor TP, Wade TP, Sunwoo YC i wsp. Small cell undifferentiated carcinoma of the pancreas. Report of a patient with tumor marker studies. Cancer 1992; 70: 1514-1519.
42. Reyes CV, Wang T. Undifferentiated small cell carcinoma of the pancreas a report of five cases. Cancer 1981; 47: 2500-2502.
43. DeLellis RA, Lioyd RV, Heitz PU i wsp. Pathology and Genetics of Tumors of Endocrine Organs. IARC Press, Lyon 2004: 67-72.
44. Nilsson O, Van Cutsem E, Fave GD i wsp. Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic). Neuroendocrinology 2006; 84: 212-215.
45. Service FJ. Insulinoma and other islet-cell tumors. Cancer Treat Res 1997; 89: 335-346.
46. Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332: 1144-1152.
47. Öberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 799-805.
48. Mignon M, Cadiot G. Natural history of gastrinoma: lessons from the past. Ital J Gastroenterol Hepatol 1999; 31 (supl. 2): 98-103.
49. Roy P, Venzon DJ, Shojamanesh H i wsp. Zollinger-Ellison syndrome clinical presentation in 261 patients. Medicine 2000; 79: 379-411.
50. Roy P, Venzon DJ, Feigenbaum KM i wsp. Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis. A prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 2001; 80: 189-222.
51. Gibril F, Jensen RT. Zollinger-Ellison syndrome revisited: diagnosis, biologic, markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004; 6: 454-463.
52. Jensen RT. Gastrinomas: advances in diagnosis and management. Neuroendocrinology 2004; 80: 23-27.
53. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis and treatment. Endocr Rev 1981; 2: 347-361.
54. Zeng J, Wang B, Ma D i wsp. Glucagonoma syndrome: diagnosis and treatment. J Am Acad Dermatol 2003; 48: 297-298.
55. Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol 2005; 19: 807-817.
56. Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of non-functioning neuroendocrine tumors of the pancreas. Br J Surg 1993; 80: 625-627.
57. Madura JA, Cummings OW, Wiebke EA i wsp. Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997; 63: 573-578.
58. Matthews BD, Heniford BT, Reardon PR i wsp. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000; 66: 1116-1123.
59. White TJ, Edney JA, Thompson JS i wsp. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 1994; 168: 627-629.
60. Corrin B, Gilby ED, Jones NF i wsp. Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer 1973; 31: 1523-1527.
61. Gordon DL, Lo MC, Schwartz MA. Carcinoid of the pancreas. Am J Med 1971; 51: 412-415.
62. Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab 2000; 85: 3973-3974.
63. Campana D, Pisciteli L, Mazotta A. Zollinger-Ellison syndrome. Diagnosis and therapy. Minerva Med 2005; 96: 187-206.
64. Hirsowitz BI. Zollinger-Ellison syndrome: pathogenesis, diagnosis and management. Am J Gastroenterol 1997; 92 (supl. 4): 44-48.
65. Plockinger U, Rindi G, Arnold R i wsp. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004; 80: 394-424.
66. Cruz-Bautista I, Lerman I, Perez-Enriquez B i wsp. Diagnostic challenge of glucagonoma: case report and literature review. Endocr Pract 2006; 12: 422-426.
67. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
68. Nasierowska-Guttmejer A, Malinowska M. Guzy neuroendokrynne układu pokarmowego (GEP/NET) - dyskusja wokół nazewnictwa i klasyfikacji. Przeg Gastroenterol 2006; 1: 1-4.
69. Nasierowska-Guttmejer A. Patomorfologia guzów neuroendokrynnych układu pokarmowego. Wydanie specjalne Onkologia po Dyplomie 2005: 25-30.
70. DeLellis RA, Lloyd RV, Hertz PU i wsp. Word Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon 2004.
71. Klöpell G, Rindi G, Anlauf M i wsp. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451 (supl. 1): 9-27
72. Rindi G, Klöppel G, Alhman H i wsp. TNM staging of foregut (neuro) endocrine tumors: a consensus propos al including a trading system. Virchows Arch 2006; 449: 395-401.
73. Nilsson O, Van Cutsem E, Fave GD i wsp. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006; 84: 212-215.
74. Kaltsas G, Rockall A, Papadogias D i wsp. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.
75. Zimmer T, Stolzel U, Bader M i wsp. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39: 562-568.
76. Ramage JK, Davies AH, Ardill J i wsp. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (supl. 4): iv1-iv16.
77. Rösch T, Lightdale CJ, Botet JF i wsp. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721-1726.
78. Pitre J, Soubrane O, Palazzo L i wsp. Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas 1996; 13: 55-60.
79. Schumacher B, Lubkay HJ, Frieling T i wsp. Prospective study on detection of insulinomas by endoscopic ultrasonography. Endoscopy 1996; 28: 273-276.
80. Gouya H, Vignaux O, Augui J i wsp. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 2003; 181: 987-92.
81. Zimmer T, Scherübl H, Faiss S i wsp. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000; 62 (supl. 1): 45-50.
82. Anderson MA, Carpenter S, Thompson NW i wsp. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumours of the pancreas. Am J Gastroenterol 2000; 95: 2271-2277.
83. Ardengh JC, Rosenbaum P, Ganc AJ i wsp. Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 2000; 51: 552-555.
84. Ruszniewski P, Amouyal P, Amouyal G i wsp. Localisation of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635.
85. Sugiyama M, Nobutsugu A, Yumi I i wsp. Differential diagnosis of benign versus malignant non-functioning islet cell tumours of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc 2002; 55: 115-119.
86. Tio TL, Sie LH, Kallumaris G i wsp. Staging of ampullary and pancreatic carcinoma: comparison between endosonography and surgery. Gastrointest Endosc 1996; 44: 706-713.
87. Voss M, Hammel P, Molas G i wsp. Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut 2000; 46: 244-249.
88. Hocke M, Schulze E, Gottschalk P i wsp. Contrast-enhanced endoscopic ultrasound in discrimination between focal pancreatitis and pancreatic cancer. World J Gastroenterol 2006; 12: 246-250.
89. th National Congress. Milan. J Pancreas 2006; 7: 558 (abstract).
90. Kos-Kudła B, Ćwikła J, Jarza̧b B i wsp. Polskie zalecenia diagnostyczno-lecznicze w guzach neuroendokrynnych układu pokarmowego (GEP NET). Endokrynol Pol 2006: 57: 267-272.
91. Norton JA, Sigel B, Baker AR i wsp. Localization of an occult insulinoma by intraoperative ultrasonography. Surgery 1985; 97: 381-384.
92. Kuzin NM, Egorov AV, Kondrashin SA i wsp. Preoperative and intraoperative topographic diagnosis of insulinomas. World J Surg 1998; 22: 593-597.
93. Machado MC, da Cunha JE, Jukemura J i wsp. Insulinoma: diagnostic strategies and surgical treatment. A 22-year experience. Hepatogastroenterology 2001; 48: 854-858.
94. King CM, Reznek RH, Dacie JE i wsp. Imaging islet cell tumours. Clin Radiol 1994; 49: 295-303.
95. Grant CS. Gastrointestinal endocrine tumours. Insulinoma. Bailleres Clin Gastroenterol 1996; 10: 645-671.
96. Jansen RT. Gastrointestinal endocrine tumours. Gastrinoma. Bailleres Clin Gastroenterol 1996; 10: 603-643.
97. Ricke J, Klose KJ, Mignon M i wsp. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37: 8-17.
98. Anderson MA, Carpenter S, Thompson NW i wsp. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95: 2271-2277.
99. Ćwikła JB, Walecki J. Diagnostyka obrazowa guzów neuroendokrynnych trzustki z elementami leczenia radioizotopowego. Przegl Gastroenterol 2006; 1: 31-44.
100. Prokop M, Galanski M, Molen AJ i wsp. Spiral and multislice computed tomography of the body. Thieme, Stuttgart, New York 2001.
101. Gouya H, Vignaux O, Augui J i wsp. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 2003; 181: 987-992.
102. Gibril F, Reynolds JC, Doppman JL i wsp. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125: 26-34.
103. Chiti A, Fanti S, Savelli G i wsp. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25: 1396-1403.
104. Öberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-781.
105. Owen NJ, Sohaib SA, Peppercorn PD i wsp. MRI of pancreatic neuroendocrine tumours. Br J Radiol 2001; 74: 968-973.
106. Tajima Y, Kuroki T, Tsutsumi R i wsp. Pancreatic carcinoma coexisting with chronic pancreatitis versus tumor-forming pancreatitis: diagnostic utility of the time-signal intensity curve from dynamic contrast-enhanced MR imaging. World J Gastroenterol 2007; 13: 858-865.
107. Thoeni RF, Mueller-Lisse UG, Chan R i wsp. Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214: 483-490.
108. Reubi JC, Shar JC, Waser B i wsp. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
109. Öberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 265-276.
110. Cholewinski W, Tarkowska A. Ligandy receptorów somatostatynowych w diagnostyce i terapii radioizotopowej w onkologii. Nowotwory 2002; 52: 227-234.
111. Krenning EP, Kwekkeboom DJ, Bakker WH i wsp. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
112. Guillermet-Guibert J, Lahlou H, Pyronnet S i wsp. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol 2005; 19: 535-551.
113. Schillaci O, Spanu A, Scopinaro F i wsp. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003; 23: 1687-1695.
114. Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R i wsp. (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006; 33: 1123-1133.
115. Reubi JC, Waser B, Schaer JC i wsp. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-846.
116. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793.
117. Krenning EP, Kwekkeboom DJ, Reubi JC i wsp. 111In-octreotide scintigraphy in oncology. Metabolism 1992; 41: 83-86.
118. de Herder WW, Kwekkeboom DJ, Valkema R i wsp. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005; 28: 132-136.
119. Gibril F, Reynolds JC, Chen CC i wsp. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40: 539-553.
120. de Kerviler E, Cadiot G, Lebtahi R i wsp. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med 1994; 21: 1191-1197.
121. Lebtahi R, Cadiot G, Sarda L i wsp. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853-858.
122. Schillaci O, Spanu A, Scopinaro F i wsp. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003; 44: 359-368.
123. Chiti A, Briganti V, Fanti S i wsp. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000; 44: 42-49.
124. Cimitan M, Buonadonna A, Cannizzaro R i wsp. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003; 14: 1135-1141.
125. Lebtahi R, Cadiot G, Marmuse JP i wsp. False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med 1997; 38: 1979-1981.
126. Joseph K, Stapp J, Reinecke J i wsp. Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors]. Nuklearmedizin 1993; 32: 299-305.
127. Jamar F, Fiasse R, Leners N i wsp. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995; 36: 542-549.
128. Ellison EC, Schirmer WJ, Olsen JO i wsp. Localization of neuroendocrine tumors using somatostatin receptor imaging with Indium-111-Pentetreotide (OctreoScan). Cancer Control 1997; 4: 35-39.
129. Schillaci O, Corleto VD, Annibale B i wsp. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31: 186-189.
130. Schillaci O, Massa R, Scopinaro F. 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000; 41: 459-462.
131. Gabriel M, Muehllechner P, Decristoforo C i wsp. 99mTc-EDDA//HYNIC-Tyr(3) -octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Q J Nucl Med Mol Imaging 2005; 49: 237-244.
132. Gabriel M, Decristoforo C, Donnemiller E i wsp. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003; 44: 708-716.
133. Gabriel M, Decristoforo C, Maina T i wsp. 99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm 2004; 19: 73-79.
134. d'Amico A, Szczucka K, Borys D i wsp. SPECT-CT fusion: a new diagnostic tool for endocrinology. Endokrynol Pol 2006; 57: 71-74.
135. Krausz Y, Keidar Z, Kogan I i wsp. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59: 565-573.
136. Rufini V, Calgani ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228-247.
137. Anderson CJ, Dehdashti F, Cutler PD i wsp. 64Cu-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42: 213-221.
138. 111In DTPA-D-Phe-octreotide and scintillation a detector. Eur J Nucl Med 2001; 28: 1456-1462.
139. Adams S, Baum RP. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med 2000; 44: 59-67.
140. 99mTc-EDDA/HYNIC-TOC is a suitable radiopharmaceutical for radioguided surgery of neuroendocrine tumours [abstract]. International Symposium on Trends in Rdiopharmaceuticals (ISTR) 2005.
141. 99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of gastrointestinal tract (GEP-NET). Eur J Nucl Med Mol Imaging 2007; 34: 1545-1555.
142. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol 1999; 10: 182-184.
143. Hiramoto JS, Feldstein VA, LaBerge JM i wsp. Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 2001; 136: 1020-1025.
144. Grover AC, Skarulis M, Alexander HR i wsp. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005; 138: 1003-1008.
145. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 229-239.
146. Yu F, Venzon DJ, Serrano J i wsp. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630.
147. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120: 139-161.
148. Norton JA, Fraker DL, Alexander HR i wsp. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644.
149. Gibril F, Reynolds JC, Chen CC i wsp. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40: 539-553.
150. Termanini B, Gibril F, Reynolds JC i wsp. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-347.
151. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005; 128: 1668-1684.
152. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996; 71: 1030-1038.
153. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17: 389-400.
154. Schillaci O, Spanu A, Scopinaro F i wsp. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003; 23: 1687-1695.
155. Kos-Kudła B, Zemczak A. Współczesne metody rozpoznawania i leczenia guzów neuroendokrynnych układu pokarmowego. Endokrynol Pol 2006; 57: 174-185.
156. Aranha GV. Shoup M. Nonstandard pancreatic resections for unusual lesions. Am J Surg 2005; 189: 223-228.
157. Bernards FJ, Cuesta MA, Kazemier G i wsp. Laparoscopic detection and resection of insulinomas. Surgery 2000; 128: 386-391.
158. Stabile BE. Islet cell tumors. Gastroenterologist 1997; 5: 213-232.
159. Stehouwer CD, Lems WF, Fischer HR i wsp. Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analoque octreotide (SMS 201-995) more effective than single therapy with either drug? Neth J Med 1989; 35: 86-94.
160. Brodows RG, Campbell RG. Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. J Clin Endocrinol Metab 1974; 38: 159-162.
161. Lamberts SW, van der Lely AJ, de Herder WW i wsp. Octreotide. N Engl J Med 1996; 334: 246-254.
162. Stehouwer CD, Lems WF, Fischer HR i wsp. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (sandostatin). Acta Endocrinol (Copenh) 1989; 121: 34-40.
163. Erikcson B, Öberg K, Alm G i wsp. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986; 11: 1307-1309.
164. Kwakkeboom DJ, Teunissen JJ, Bakker WH i wsp. Radiolabeled somatostatin analog [177LU-DOTA0, Tyr3] octreotate in patients with endocrine gastropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
165. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumors. Endocr Relat Cancer 2003; 10: 463-468.
166. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors.Digestion 2000; 62 (supl. 1): 73-78.
167. Metz DC, Strader DB, Orbuch M i wsp. Use of omeprazole in Zollinger-Ellison: A prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-810.
168. Termanini B, Gibril F, Sutliff VE i wsp. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 1998; 104: 422-430.
169. Norton JA, Cornelius MJ, Doppman J i wsp. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1: a prospective study. Surgery 1987; 102: 958-966.
170. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488.
171. Aparicio T, Ducreux M, Baudin E i wsp. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 1014-1019
172. Öberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001; 12 (supl. 2): 111-114.
173. Gorden P, Comi RJ, Maton PN i wsp. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110 (1): 35-50.
174. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996; 71: 1030-1038.
175. Kouvaraki MA, Ajani JA, Hoff P i wsp. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-4771.
176. Alexander EK, Robinson M, Staniec M i wsp. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol (Oxf) 2002; 57: 827-831.
177. Sinclair SA, Reynolds NJ. Necrolytic migratory erythema and zinc deficiency. Br J Dermatol 1997; 136: 783-785.
178. Nguyen HN, Backes B, Lammert F i wsp. Long-term survival after diagnosis of hepatic metastatic vipoma: report of two cases with disparate courses and reviews of therapeutic options. Dig Dis Sci 1999; 44: 1148-1155.
179. Panzuto F, Di Fonzo M, Iannicelli E i wsp. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated enteropancreatic endocrine carcinoma. Ann Oncol 2006; 17: 461-466.
180. Fine R, Fogelman D, Schreibman SM. Effective tratment of neuroendocrine tumors with temozolomide and capecitabine. ASCO Proccedings 2005; 4416.
181. Lankat-Buttgereit B, Horsch D, Barth P i wsp. Effects of the tyrosine kinase inhibitor imatinib on neuroendocirne tumor cell growth. Digestion 2005; 71: 131-140.
182. Ramanathan RK, Cnaan A, Hahn RG i wsp. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group - E6282. Ann Oncol 2001; 12: 1139-1143.
183. Sun W, Lipsitz S, Catalano P i wsp. Phase II/III study of doxorubicin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors. Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904.
184. Moertel CG, Kvols LK, O'Connel MJ i wsp. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
185. Öberg K, Ahlman H. Medical management of neuroendocrine gastrointestinal tumors. W: Schwartz A, Gagnier M, Pertsemlides D (red.). Endocrine Surgery. Marcel Dekker, New York 2004; 685-696.
186. Fjällskog ML, Granberg DP, Welin Sl i wsp. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107.
187. De Jong M, Bakker WH, Breeman WA i wsp. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3]octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75: 406-411.
188. Paganelli G, Zoboli S, Cremonesi M i wsp. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Otreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 1999; 14: 477-483.
189. McStay MK, Maudgil D, Williams M i wsp. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237: 718-726.
190. Krenning EP, Kwekkeboom DJ, Valkema R i wsp. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004; 1014: 234-245.
191. Waldherr C, Schumacher T, Maecke HR i wsp. Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 2002; 29: S100.
192. Frilling A, Weber F, Saner F i wsp. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006; 140: 968-976.
193. Virgolini I, Britton K, Buscombe J i wsp. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-155.
194. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46: 67-75.
195. Krenning EP, Kwekkeboom DJ, Valkema R i wsp. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004; 1014: 234-245.